• Javier Molina-Infante and Alfredo J Lucendo.
• Department of Gastroenterology, Hospital San Pedro de Alcantara, C/ Pablo Naranjo s/n 10003, Caceres, Spain.
• Expert Rev Gastroenterol Hepatol. 2014 Nov 1; 8 (8): 925-34.

AbstractEosinophilic esophagitis (EoE) has emerged as a common cause of dysphagia and food impaction in children and adults. A trial of proton pump inhibitor (PPI) therapy is a mandatory diagnostic first step, given that at least one third of patients with suspected EoE will have PPI-responsive esophageal eosinophilia. Once EoE is diagnosed, short-and long-term therapeutic decision making may rely on patient symptoms, phenotype (inflammatory vs fibrostenotic) and preferences. Currently, the most reliable therapeutic targets are mucosal healing and caliber abnormalities resolution. Topical steroids followed by endoscopic dilation are recommended in symptomatic narrow caliber esophagus/strictures, whereas either topical steroids or dietary therapy are good short-term options for mucosal inflammation. Maintenance anti-inflammatory therapy is necessary to prevent esophageal fibrotic remodeling and stricture formation.

14 keywords...

hide…